6 July 2020 - - US-based life sciences solutions company Trinity Life Sciences has launched the first weekly-updated, forecasting model for drugs and treatments impacted by COVID-19, the company said.

Trinity COVIDCast is a flexible SEIR (susceptible, exposed, infectious, recovered) model that forecasts COVID-19 case counts and hospitalizations across the United States, EU5, China and Japan.

COVIDCast is designed for forecasting or brand planning teams working on COVID-specific drugs, diagnostics and vaccines as well as for teams who are working to forecast the impact on non-COVID drugs due to the virus.

Trinity COVIDCast is designed to be flexible in the face of emerging scientific literature, adaptive to the most recent case data and pliable to emerging consensus from public health experts on plausible real-world scenarios.

The models can be configured for any new or existing forecast using a combination of Excel and web-enabled toolsets. Weekly updates are compatible with TrinityEDGE, Trinity's proprietary technology platform for data, analytics and reporting.

COVIDCast includes multiple pre-built scenarios with the ability to plug in proprietary assumptions. The model is highly configurable to apply to any situation or therapy that is affected by the spread of COVID-19 and the resulting cascade of impacts.

Trinity Life Sciences is a strategic partner, providing evidence-based solutions for the life sciences.

Trinity's range of products and solutions includes benchmarking solutions, powered by TGaS Advisors.